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Background: The standard treatment for non-metastatic muscle-invasive bladder cancer (stages T2–T4a) is radical
cystectomy with lymphadenectomy. However, patients undergoing cystectomy show metastatic spread in 25% of
cases and these patients will have limited benefit from surgery. Identification of patients with high risk of lymph
node metastasis will help select patients that may benefit from neoadjuvant and/or adjuvant chemotherapy.
Methods: RNA was procured by laser micro dissection of primary bladder tumors and corresponding lymph node
metastases for Affymetrix U133 Plus 2.0 Gene Chip expression profiling. A publically available dataset was used for
identification of the best candidate markers, and these were validated using immunohistochemistry in an
independent patient cohort of 368 patients.
Results: Gene Set Enrichment Analysis showed significant enrichment for e.g. metastatic signatures in the
metastasizing tumors, and a set of 12 genes significantly associated with lymph node metastasis was identified.
Tumors did not cluster according to their metastatic ability when analyzing gene expression profiles using
hierarchical cluster analysis. However, half (6/12) of the primary tumor clustered together with matching lymph
node metastases, indicating a large degree of intra-patient similarity in these patients. Immunohistochemical
analysis of 368 tumors from cystectomized patients showed high expression of GEM (P = 0.033; HR = 1.46) and
EDNRA (P = 0.046; HR = 1.60) was significantly associated with decreased cancer-specific survival.
Conclusions: GEM and EDNRA were identified as promising prognostic markers for patients with advanced bladder
cancer. The clinical relevance of GEM and EDNRA should be evaluated in independent prospective studies.
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Bladder cancer is the 4th most common cancer in men and
the 11th most common cancer in women [1]. Patients with
non-muscle-invasive bladder cancer (NMIBC) are predom-
inantly treated with transurethral resection of the bladder
in combination with Bacillus Calmette-Guerin (BCG) or
Mitomycin C. Cystectomy is offered if local control cannot
be maintained. Recently, treatment of NMIBC has shifted
towards a more aggressive approach based on EORTC risk
scores, resulting in more patients receiving cystectomy* Correspondence: lars@clin.au.dk
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unless otherwise stated.[2,3]. The standard treatment for non-metastatic muscle-
invasive bladder cancer (MIBC) (stages T2–T4a) is radical
cystectomy with lymphadenectomy [4]. Patients with im-
mobile tumors (T4b) receive chemotherapy– sometimes
followed by salvage cystectomy or radiotherapy [5]. Five-
year cancer-specific survival for patients with MIBC is 65%
following cystectomy and neoadjuvant chemotherapy in-
creases the 5-year survival with 6–8% but is, for now, not
standard treatment in all clinical settings [6,7].
Patients undergoing cystectomy show metastatic spread
in 25% of cases [8], and these patients will have limited
benefit of surgery. Identification of patients with high risk
of lymph node metastasis could help identify patients that
would benefit from neoadjuvant chemotherapy. Therefore,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tant organs) prior to cystectomy is of high importance.
Previously, several studies have focused on studying mo-
lecular markers to identify metastatic risk or ability based
on analysis of the patient’s primary tumor. Key players in
the DNA-damage-response and cell-cycle machinery (e.g.
p53, Rb, p21, p16, Tip60) have been investigated by immu-
nohistochemistry, but none of the markers have shown sig-
nificant power in validation studies to reach the clinic
[9-12]. More recently, gene-expression signatures have re-
vealed promising results but have not yet been validated in
prospective patient cohorts [13,14]. Smith et al. reported a
20 gene signature in the primary tumor for predicting
lymph node metastasis based on three different cohorts,
making it the first study in MIBC where the gene signature
was validated in an independent patient cohort [15].
Patients with high relative risk (1.74) and low relative risk
(0.70) of node positive disease could be identified. In other
disease like e.g. breast cancer, metastatic capacity of the
primary tumors has been studied intensely, and several
gene expression signatures for predicting metastatic out-
come have been develop and successfully validated [16-19].
Here we laser micro dissected primary bladder tumors
and corresponding lymph node metastases and performed
microarray gene expression profiling of the procured cells.
We compared gene expression patterns in primary blad-
der tumors with and without metastatic disease and by in-
cluding previously published data from Riester et al. [20]
we identified a panel of 12 transcripts significantly associ-
ated with disease outcome. The prognostic value of GEM
(GTP binding protein overexpressed in skeletal muscle)
and EDNRA (endothelin receptor type A) were success-




Written informed consent was obtained from all patients
and the study was approved by the Central Denmark
Region Committees on Biomedical Research Ethics (1994/
2920). All patients were cystectomized at Department of
Urology at Aarhus University Hospital between 1998
and 2008, and surviving patients had at least 36 months
of follow-up, and were censored after a maximum of
96 months. Tumor stage was determined using the Ameri-
can Joint Committee on Cancer recommendations from
2002 and WHO 2004 classification was used to determine
tumor grade. All patients were clinically free of metastasis
before surgery and no patients received neoadjuvant or ad-
juvant treatment in terms of chemotherapy or radiotherapy.
Laser micro dissection, RNA extraction and microarray analysis
All patient specimens collected at the time of surgery
were split into tissue for pathology and tissue for thebiobank. Tissue for the biobank was embedded in
Tissue-Tek® O.C.T™ Compound and snap frozen in li-
quid nitrogen before storage at −80°C. Sections were ex-
amined by a genitourinary pathologist to identify
carcinoma cell content. Following, cresyl violet stained
tissue was microdissected using the PALM laser micro-
beam system. RNA extraction was performed using
RNeasy Micro Kits (Qiagen) according to manufacturer
protocols. RNA quality was assessed using an Agilent
Bioanalyzer 2100 (RIN: 2.4-8.8; median 5.9). Total RNA
was amplified and converted to cDNA using Nugen
Pico-RNA system. The two-round amplification kit is
optimized to amplify low volumes and poor quality RNA
for Affymetrix array analysis. After amplification, the
cDNA was fragmented and labeled using NuGen FL-
Ovation kit, loaded onto the Affymetrix U133 Plus 2.0
Gene Chip according to the manufacturer’s protocol,
and scanned using the Affymetrix 3000 7G Scanner.
Microarray data analysis
Raw microarray data was normalized and intensity mea-
sures generated by RMA [21] using GeneSpring version
11 software. Unsupervised hierarchical cluster analysis of
all transcripts with a variance above 1.5 was performed
using Cluster 3.0 and Java tree-view software [22]. Gene
Set Enrichment Analysis (GSEA) v2.07 software was
used to test if previously published gene signatures and
curated pathways were enriched in the data. We used
the inbuilt KEGG, BIOCARTA, REACTOME, gene
ontology, and oncogenic signatures in MsigDB database
and supplemented with curated signatures containing
“cancer”, “metastasis”, “cell cycle”, “repair”, “DNA dam-
age”, and “hypoxia”. We used the default significance
levels to test if significant enrichment was reached with
normalized p-values below 0.05 and with false discovery
rates below 0.25. A previously published dataset (GEO
ID: GSE31684; U133 Plus 2.0 GeneChip) from laser mi-
crodissected tumors from 93 cystectomized patients was
retrieved. A total of 69 patients were included in the
analysis, after exclusion of all patients without reported
lymph node status, and all node negative patients with-
out 24 months of follow-up.
Tissue microarray (TMA) analysis
Biopsies from a total of 368 tumors from cystectomy
specimens and from 41 lymph node metastases were in-
corporated into a TMA. All tumors were reevaluated re-
garding T-stage and grade by the same uro-pathologist
prior to placement on the TMA. The patients included
and the TMA construction is described earlier [11].
Immunohistochemistry and Western blotting
The immunohistochemichal staining procedure was car-
ried out based on the EnVision + TM System HRP (Dako)
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(Novus Biologicals # NBP1-58906) diluted 1:150 and
against EDNRA (Abcam #ab76259) diluted 1:800 were
used. The specificity of the antibodies against GEM and
EDNRA was validated by Western blotting using T24 cell
line essentially as described earlier [24].
Scoring of IHC staining
A Hamamatsu Nanozoomer scanner (Hamamatsu Cor-
poration, Hamamatsu City, Japan) was used to scan the
TMA slides, and VIS visualization software (Visiopharm
A/S, Hørsholm, Denmark) was used for visualization of
IHC staining during scoring of the protein expression
intensities. Percentage of positive carcinoma cells was
scored on a continuous scale for each core, and optimal
cut-off values were afterwards defined by ROC curves.
Scoring was performed by two observers blinded to out-
come. The first observer scored on a continuous scale,
and the second scored according to the dichotomized
cutoff value generated. Differences in the dichotomized
scorings were reviewed and consensus was reached.
Statistics
Comparisons between the metastatic and non-metastatic
groups were performed using two-sided t-test statistics.
Categorical data was compared in univariate analysis using
the χ2 test and censored data was compared using log-rank
test. Hazard ratios (HR) were estimated using Cox propor-
tional hazard models. Multivariate analysis was performedTable 1 Clinical and histopathological information for each p
Patient Gender T-stage N status Relapse Dead of B
2211 Man 4a Positive No
1599 Woman 1 Positive No
2114 Man 3b Positive Yes
2117 Man 3b Positive No
2130 Man 1 Positive Yes
2163 Man 2 Positive No
2180 Man 3 Positive Yes
2207 Man 4a Positive Yes
2249 Woman 1 Positive Yes
2237 Woman 2 Positive No
1956 Man 1 Negative No
1930 Man 1 Negative No
1940 Woman 2 Negative No
1743 Man 1 Negative Yes
2036 Man 2 Negative No
1874 Man 3b Negative No
1607 Woman 2 Negative No
1956 Man 1 Negative Noseparately for each biomarker including only significant
clinical parameter from the univariate analysis. All analyses
were performed using STATA (version 11).
Results
For gene expression profiling we selected 18 primary
tumors and 12 matched lymph node metastases from
18 patients with bladder cancer. Ten patients had at
least one lymph node metastasis at time of cystectomy,
and 6 patients died of bladder cancer. Clinical and
histopathological information for each patient is listed
in Table 1.
Molecular subgroup analysis
Initially, data was filtered, selecting only transcripts with a
variance above 1.5 across all samples (11046 transcripts).
We performed unsupervised hierarchical cluster analysis to
investigate if tumors clustered based on stage or metastatic
abilities, and if lymph nodes showed a high degree of simi-
larity to the matched primary tumors (Figure 1). Cluster
analysis separated the tumors into two main clusters; one
cluster (cluster A) contained seven primary metastasizing
tumors, three primary non-metastasizing tumors, and eight
lymph nodes, and among these were six of the seven
matched pairs. The other cluster (cluster B) contained five
primary non-metastasizing tumors, five metastasizing pri-
mary tumors, and four lymph nodes. Seven of the lymph
nodes clustered together with their matched primary
tumor, indicating a large degree of intra-patient similarityatient used for gene expression profiling



















Figure 1 Unsupervised hierarchical cluster analysis of all samples. Square brackets are used when the coupled tumor and metastasis cluster
together. Green color represents a primary non-metastasizing tumor. Dark green represents a primary non-metastasizing tumor which later develops
lymph node metastases in the abdomen. Blue color represents a primary metastasizing tumor. Red color represents a lymph node metastasis.
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did not show significant separation of the tumors based on
metastatic ability. Most of the muscle-invasive tumors
clustered together in cluster A – as expected.
Gene set enrichment analysis (GSEA)
To investigate the differences between the metastatic
and non-metastatic tumors more specifically, we applied
GSEA for investigating enrichment for previously pub-
lished signatures regarding key elements in the meta-
static process together with enrichment for pathway
elements (Table 2). Interestingly, all signatures regarding
extracellular function, metastasis, hypoxia, proliferation,and survival were exclusively enriched in metastatic tu-
mors while all signatures regarding repair and cell cycle
were enriched in non-metastatic tumors. Cell signaling
was primarily enriched in metastatic tumors while me-
tabolism was primarily enriched in non-metastatic tu-
mors. In addition, we investigated enrichment for
previously published signatures comparing primary tu-
mors and metastasis [25-27]; both signatures containing
tumors from many different tissues were significantly
enriched in our dataset (Ramaswamy et al., P = 0.02 and
Daves et al., P = 0.03), while the signature from meta-
static malignant melanoma was borderline significantly
enriched (Daves et al., P = 0.06).





Extracellular function 10 0
Metastasis 7 0
Proliferation and survival 7 0
Hypoxia up 1 0
Cell signaling 20 6
Metabolism 8 13
Hypoxia down 0 1
Repair 0 15
Cell cycle 0 33
Others 17 32
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We used the paired tumors and lymph node metastases
to investigate the intra- and inter-patient similarity.
When comparing differences in transcript levels between
the matched primary tumors and metastases using two-
fold difference as cut-off, we did not find any transcripts
that were differentially expressed in all 12 tumor-lymph
node comparisons (Figure 2). MMP2 was the only gene
that was down-regulated in 11 lymph node metastases,
while 18 transcripts were up or down regulated in 10
lymph node metastases. In general, as observed in the
cluster analysis, the patients show a large heterogeneityFigure 2 Tumor heterogeneity measures. The distribution of transcripts w
Two lymph node metastases were included from two patients resulting in 12in expression patterns between primary tumors and
lymph node metastases. Using Ingenuity Pathway Ana-
lysis we did not identify any general pathway changes
between primary tumors and lymph node metastases,
probably because of this large heterogeneity observed
between patients.
Identification of markers associated with outcome
Because of the large heterogeneity observed and because
of the limited sample size we included a previously pub-
lished dataset for delineation of markers associated with
outcome (GEO ID: GSE31684). The dataset contained
Affymetrix U133 Plus 2.0 GeneChip data from 69 pa-
tients with known lymph node status and at least
24 months of follow-up if no lymph node metastasis was
present at surgery. Separately, for both datasets, we de-
lineated transcripts associated with the presence or ab-
sence of metastasis; only transcripts with a mean fold
change difference > 2 and with a P < 0.05 (student’s t-
test) were selected. Twelve transcripts up-regulated in
metastasizing tumors passed our selection criteria in
both datasets (Table 3). We selected EDNRA and GEM
(Figure 3) for further validation using immunohisto-
chemistry (IHC). For this we used a tissue microarray
containing 409 core biopsies from both primary tumors
(n = 368) and lymph node metastases (n = 41). Both
GEM and EDNRA protein expression was localized in
the cytoplasm of the cells, and no staining was observed
in normal urothelium or connective tissue cells. IHCith more than two-fold difference in tumor-metastasis pair comparisons.
comparisons in total.
Table 3 Transcripts significantly up-regulated in metastasizing tumors in both cohorts
Non-metastatic vs metastatic
tumors
Lymph node metastasis vs non-metastatic
tumors
Non-metastatic vs metastatic tumors
(Riester et al.)
Transcript p-value FC p-value FC p-value FC
COL6A2 0.0397 1.0967 0.7515 0.1176 0.0461 1.7263
LMCD1 0.0248 1.1631 0.0036 1.7576 0.0196 1.7212
FZD1 0.0287 1.5193 0.0878 1.1318 0.0055 1.0648
MITF 0.0364 1.6083 0.4593 −0.3003 0.0164 1.0783
EDNRA 0.0051 1.6613 0.0181 1.0262 0.0177 1.4840
EBF1 0.0211 1.7592 0.0168 1.8477 0.0149 1.0386
TPST1 0.0199 1.7953 0.1975 0.8709 0.0318 1.1064
AEBP1 0.0242 2.2697 0.0077 1.6563 0.0072 3.0447
PALLD 0.0344 2.3131 0.1163 0.9763 0.0104 1.4558
GEM 0.0121 2.3136 0.0000 3.2533 0.0219 1.5247
PXDN 0.0044 3.1464 0.0042 1.8611 0.0356 1.9232
KITLG 0.0110 3.3621 0.0537 1.6857 0.0323 1.1616
FC = Log 2 fold change differences.
Bold indicates significant p-values when comparing lymph node metastasis and non-metastatic tumors.
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with an inter-observer agreement of 0.70 (GEM) and of
0.81 (EDNRA), using Cohen’s kappa. The clinical and
histopathological characteristics for the patients included
in this cohort are listed in Table 4. High expression of
GEM (P = 0.033; HR = 1.46) and EDNRA (P = 0.046;
HR = 1.60) were significantly associated with decreased
cancer-specific survival (Figure 4). Furthermore, after per-
forming multivariate analysis high EDRNA expression
showed significantly association with decreased cancer-Figure 3 Differences in GEM and EDNRA expression in primary non-m
and lymph nodes metastases (M).specific survival (P = 0.046), while GEM showed no sig-
nificance (P = 0.11). Finally we investigated the similarity
in protein expression between matched primary tumors
and lymph node metastases; 94% of the lymph nodes
showed similar expression as in the primary tumors for
EDNRA and 71% for GEM.
Discussion
The risk of recurrence and later metastasis following
cystectomy is as high as 50% [28] and most patients willetastasizing tumors (PNT), primary metastasizing tumors (PMT),
Table 4 Univariate and multivariate Cox regression analysis of disease specific survival as function of molecular
markers




Nr. of patients 368
Median Follow-up months (range) 62 (2–96)
Age median (range) 64 (39–79) HR = 1.01 (P=0.47)
Sex HR = 1.56 (P=0.007) HR = 1.62 (P=0.015) HR = 1.45 (P=0.048)
Men 268
Women 100





Lymph node metastases HR = 3.98 (P<0.001) HR = 3.82 (P<0.001) HR = 3.55 (P<0.001)
N0 278 (76%)
N1-3 89 (24%)
Grade HR = 1.18 (P=0.78)
Low grade 8 (2%)
High grade 360 (98%)
EDNRA HR = 1.60 (P=0.046) HR = 1.63 (P=0.042)
High 206 (76%)
Low 65 (24%)
GEM HR = 1.46 (P=0.032) HR = 1.33 (P=0.11)
High 173 (59%)
Low 120 (41%)
Values in bold indicate significant uni- and multivariate analysis (P<0.05).
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[29]. Therefore, early detection of metastasis and predic-
tion of recurrence risk following cystectomy could ul-
timately improve survival as better treatment regimens
could be applied. The aim of this study was to identify
markers of lymph node metastasis at (before) cystec-
tomy. We compared gene-expression profiles from 10
primary bladder tumors with 12 matched lymph node
metastases and eight primary tumors without metastasis
to identify markers associated with metastatic disease,
and to test similarity between lymph node metastases
and matched primary tumors. Overall, we found no
large difference in gene expression between the two
patient groups. Furthermore, we found that primary
tumors and corresponding lymph node metastases
showed comparable gene expression profiles in half of
the cases. The reason for this lack of overall difference
between the groups may be caused by tumor heterogen-
eity, minor sub clones responsible for metastatic ability,and also by inclusion of tumors of different stages (T1-T4).
Gene set enrichment analysis (GSEA) was used to inves-
tigate biological differences between metastasizing and
non-metastasizing tumors. Interestingly, signatures as-
sociated with “metastasis”, “extracellular function”,
“proliferation and survival”, and “cell signaling” were
significantly enriched in the metastasizing tumors while
signatures associated with “metabolism”, “cell cycle” and
“DNA repair” were associated with non-metastatic tu-
mors – indicating that the overall biological process
may be different in the two tumor groups. However, due
to the large heterogeneity we were not able to identify
general molecular differences between lymph node me-
tastases and primary tumors.
The tumor heterogeneity (intra and inter) may make
marker identification difficult, and consequently we in-
cluded additional patient samples from a previously pub-
lished dataset [20] for delineating significant markers of
outcome. The panel of 12 genes that were significant in
Figure 4 EDNRA (A) and GEM protein (B) expression in the TMA validation cohort. Top: Staining pattern of a positive and a negative core
of EDNRA and GEM. Bottom: Kaplan-Meier survival curves of disease specific survival as a function of marker expression in the patient cohort.
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were selected for further validation based on signifi-
cance, difference in expression, expression level, and
based on antibody availability. We found no overlap be-
tween our 12 genes and the 21-gene metastasis signature
reported by Smith et al. previously [15], which may re-
flects multiple factors like cohort heterogeneity and size,
and differences in sampling (laser micro dissection vs
bulk tumor analysis). We found high expression of GEM
and EDNRA to be significantly associated with a de-
crease in cancer-specific survival, when analyzing the
protein expression on a cohort of 368 patients. Further-
more, high EDNRA was significantly associated with de-
creased cancer-specific survival in multivariate analysis.
The possible functional roles of EDNRA (endothelin re-
ceptor type A) and GEM (GTP binding protein overex-
pressed in skeletal muscle) in cancer progression and
metastasis are currently unclear. EDNRA and GEM have
not been associated with disease outcome and cancer out-
come. GEM is a small GTP-binding protein that plays a
role in regulating Ca2+ channel expression at the cell sur-
face [30]. Furthermore, it is involved in cytoskeletal re-
modeling in interphase cells and is a spindle-associated
protein required for prober mitotic progression [31].
EDNRA is a G-protein coupled receptor for endothelins
and it is expressed on vascular smooth-muscle cells and
on heart, kidney, and neuronal cells [32].This study included a limited number of tumors in the
initial characterization of tumor subgroups, and although
we isolated carcinoma cells in primary tumors and lymph
node metastases using laser-micro dissection, the patient
cohort may still be too small to draw firm conclusion re-
garding molecular subgroups and differences between pri-
mary tumors and metastatic lesions. The strength of our
approach is the inclusion of matched lymph node metas-
tasis in the selection of candidate markers for metastasis,
and this is to our knowledge the first study of bladder can-
cer that compare the lymph nodes to the primary tumors.
Recently, large intra-tumor heterogeneity of several
cancer types has been reported [33-35]. A recent study
of clear cell renal cell carcinomas showed significant
molecular heterogeneity using whole-exome sequencing
of multiple tumor areas [36]. As small cellular sub-
clones may be responsible for the disease progression
and metastasis it may be difficult to identify any good
molecular markers of outcome by analyzing the bulk tu-
mors. Other studies of tumor metastasis in mice have
shown limited overlap in genomic alterations (about 9%)
between primary tumors and metastases [37], indicating
that metastatic lesions probably propagate from small
sub-populations in the primary tumors. Intra-tumor het-
erogeneity has so far not been addressed in detail in
bladder cancer. However, Li et al. [38] performed whole-
exome sequencing of 66 individual cells from a single
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mutant genes between the cells. Other groups [39,40] have
recently shown that muscle invasive bladder cancers be-
long to 4–5 distinct molecular subgroups. Consequently,
future studies of prognostic markers for patients with ad-
vanced bladder cancer should include large patient co-
horts, stratification according to overall tumor subgroup
and sub-clonal analysis to compensate for the large inter
and intra tumor heterogeneity for these patients.
Conclusion
We observed a high degree of heterogeneity between
primary tumors with and without metastases, and be-
tween paired samples of primary tumors and associated
lymph-node metastases. GEM and EDNRA were identi-
fied to be promising prognostic markers for patients
with advanced bladder cancer. The clinical relevance of
GEM and EDNRA should be evaluated in independent
prospective studies.
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